A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01104532
First received: April 14, 2010
Last updated: April 15, 2010
Last verified: April 2010

April 14, 2010
April 15, 2010
February 2010
March 2010   (final data collection date for primary outcome measure)
Pharmacokinetic variables assessment through analysis of blood samples [ Time Frame: Day 1 to Day 15 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01104532 on ClinicalTrials.gov Archive Site
  • Pharmacodynamic variables assessment through analysis of blood and urine samples [ Time Frame: Day -1 and up to Day 11 ] [ Designated as safety issue: No ]
  • Safety assessed by recording of adverse events, laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations [ Time Frame: Day 1 through scheduled group check out (Day 11 and up to Day 15) or early termination. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects
A Phase 1, Open Label, Randomized, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP1941 and Sitagliptin After Separate and Concomitant Administration to Healthy Adult Subjects

The purpose of the study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and sitagliptin in single and multiple doses.

All subjects will be enrolled at one center and confined to the unit for up to 17 days. Subjects will be dosed in the fasting state in one of the four groups.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
  • Healthy
  • Pharmacokinetics of ASP1941
  • Drug: ASP1941
    oral tablet
  • Drug: sitagliptin
    oral tablet
    Other Name: Januvia
  • Experimental: Dosing Regimen 1
    Interventions:
    • Drug: ASP1941
    • Drug: sitagliptin
  • Experimental: Dosing Regimen 2
    Interventions:
    • Drug: ASP1941
    • Drug: sitagliptin
  • Experimental: Dosing Regimen 3
    Interventions:
    • Drug: ASP1941
    • Drug: sitagliptin
  • Experimental: Dosing Regimen 4
    Interventions:
    • Drug: ASP1941
    • Drug: sitagliptin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
64
March 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject weighs at least 50 kg, and has a body mass index (BMI) of 18 to 32 kg/m2 inclusive
  • The subject's 12-lead electrocardiogram (ECG) results are normal
  • The female subject must be at least two years postmenopausal, surgically sterile or practicing effective birth control and not pregnant or lactating
  • The male or female subject agrees to practice highly effective birth control from Screening until 7 days post last dose

Exclusion Criteria:

  • The subject has a history or evidence of any clinically significant cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy (excluding non-melanoma skin cancer)
  • The subject has evidence of renal insufficiency (serum creatinine ≥ 1.5 in men and ≥ 1.3 in women)
  • The subject has a history of cholelithiasis or acute pancreatitis
  • The subject has any condition possibly affecting drug absorption (e.g., gastrectomy)
  • The subject has history of consuming more than 14 units of alcoholic beverages per week within last 6 months or has a history of alcoholism or drug/chemical/substance abuse within past 2 years or the subject tests positive for alcohol or drugs of abuse
  • The subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check-in
  • The subject has a supine mean systolic blood pressure <90 or >160 mm/Hg and a mean diastolic blood pressure <50 or >90, or pulse rate higher than 100 beats per min (bpm)
  • The subject has a 12-lead ECG demonstrating QTcF >470 msec (female) or >450 msec (male)
  • The subject is known positive for human immunodeficiency virus (HIV) antibody
  • The subject has a positive test for tuberculosis (TB), hepatitis C antibody, or positive for hepatitis B surface antigen (HGsAg)
  • The subject has used prescription or non-prescription drugs within 14 days or 5 half-lives (whichever is longer) or complementary and alternative medicines (CAM) within 14 days prior to study drug administration (excluding oral contraceptives, hormone replacement therapy [HRT], and acetaminophen)
  • The subject has been vaccinated within the last 7 days
  • The subject has had any significant blood loss, donated one unit (450 mL) or blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01104532
1941-CL-0066
No
Sr. Manager Clinical Trials Registry, Astellas Pharma Global Development
Astellas Pharma Inc
Not Provided
Study Director: Use Central Contact Astellas Pharma Global Development
Astellas Pharma Inc
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP